Ticker > Company >

Godavari Drugs share price

Godavari Drugs Ltd.

BSE: 530317 SECTOR: Pharmaceuticals & Drugs  19.82 K   108   7

84.50
-3.38 (-3.85%)
BSE: 28 Jul 04:01 PM

Price Summary

Today's High

₹ 87.87

Today's Low

₹ 83

52 Week High

₹ 155

52 Week Low

₹ 79

FinStar is Suspended!

The FinStar rating for this company is currently unavailable due to limited data disclosure. As a micro-cap company, it may carry higher risk and limited transparency. We will update the FinStar rating once more reliable data becomes available.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

63.63 Cr.

Enterprise Value

118.78 Cr.

No. of Shares

0.75 Cr.

P/E

14.53

P/B

1.47

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  57.56

CASH

2.62 Cr.

DEBT

57.77 Cr.

Promoter Holding

52.63 %

EPS (TTM)

₹  5.82

Sales Growth

-1.82%

ROE

15.33 %

ROCE

12.63%

Profit Growth

46.57 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-1.82%
3 Year8.51%
5 Year13.41%

Profit Growth

1 Year46.57%
3 Year10.36%
5 Year35.64%

ROE%

1 Year15.33%
3 Year15.59%
5 Year15.13%

ROCE %

1 Year12.63%
3 Year14.45%
5 Year14.54%

Debt/Equity

1.4826

Price to Cash Flow

3.46

Interest Cover Ratio

2.4083

CFO/PAT (5 Yr. Avg.)

2.43527413150651

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 52.63 0.25
Mar 2025 52.63 0.25
Dec 2024 52.63 0.25
Sep 2024 52.63 0.25
Jun 2024 53.16 1.25
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company’s PEG ratio is 0.312019761891627.
  • The company has a good cash flow management; CFO/PAT stands at 2.43527413150651.
  • The company has a high promoter holding of 52.63%.

 Limitations

  • The company has shown a poor revenue growth of 8.50604811264255% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 38.64 32.21 26.09 29.55 25.5
Total Expenditure 34.17 28.98 23.18 26.98 22.39
Operating Profit 4.47 3.23 2.91 2.58 3.11
Other Income 0.11 0.77 0.01 0.1 0.11
Interest 1.23 1.44 1.08 1.11 1.11
Depreciation 0.53 0.55 0.58 0.64 0.67
Exceptional Items -0.03 0 0 0 0
Profit Before Tax 2.79 2.01 1.25 0.92 1.44
Tax 0.13 0.38 0.16 0.15 0.55
Profit After Tax 2.66 1.63 1.09 0.77 0.89
Adjusted EPS (Rs) 3.54 2.17 1.44 1.02 1.19

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 95.7 122.67 161.11 159.62 156.71
Total Expenditure 89.66 112.83 149.82 149.7 143.41
Operating Profit 6.04 9.84 11.29 9.92 13.3
Other Income 0.33 0.41 0.28 0.66 0.62
Interest 2.91 3.32 2.85 3.93 4.92
Depreciation 1.16 1.22 1.7 1.94 1.99
Exceptional Items 0 0 0 0.23 -0.09
Profit Before Tax 2.29 5.71 7.02 4.93 6.92
Tax 0.29 1.58 1.78 1.15 1.37
Net Profit 2 4.13 5.25 3.79 5.55
Adjusted EPS (Rs.) 2.66 5.48 6.97 5.03 7.37

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 7.53 7.53 7.53 7.53 7.53
Total Reserves 12.73 16.86 22.1 25.89 31.44
Borrowings 11.16 14.49 11.78 11.95 11.17
Other N/C liabilities 1.25 1.75 2.24 2.36 2.62
Current liabilities 51.25 50.51 57.76 73.71 82
Total Liabilities 83.92 91.14 101.41 121.43 134.75
Assets
Net Block 13.81 22.43 26.25 24.91 26.68
Capital WIP 8.93 0.76 0.49 9.08 18.32
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0.35 0.33 0.23 0.34 1.15
Other N/C Assets 0 0 0.1 0.1 0.11
Current Assets 60.83 67.61 74.33 87.01 88.48
Total Assets 83.92 91.14 101.41 121.43 134.75
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 2.29 5.69 7.02 4.93 6.92
Adjustment 3.75 4.13 4.27 5.22 6.29
Changes in Assets & Liabilities 0.6 -6.92 1.72 4.29 6.22
Tax Paid -0.39 -1.58 -1.78 -1.23 -1.02
Operating Cash Flow 6.24 1.33 11.23 13.22 18.41
Investing Cash Flow -6.68 -1.25 -4.97 -8.64 -13.22
Financing Cash Flow 0.34 0.13 -5.62 -3.77 -5.65
Net Cash Flow -0.1 0.21 0.64 0.81 -0.46

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 53.16 52.63 52.63 52.63 52.63
aksheit kakani 4.33 4.33 4.33 4.33 4.33
ghanshyam jaju 4.65 4.65 4.65 4.65 4.65
jaju ghanshyam huf 0.03 0.03 0.03 0.03 0.03
kamala jaju 12.08 12.08 12.08 12.08 12.08
kirti kumar jain 0.66 0.13 0.13 0.13 0.13
mohit jaju 7.10 7.10 7.10 7.10 7.10
mukund kakani 4.65 4.65 4.65 4.65 4.65
priyanka jaju 2.46 2.46 2.46 2.46 2.46
sushma kakani 15.34 15.34 15.34 15.34 15.34
tanushree kakani 1.86 1.86 1.86 1.86 1.86
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 46.84 47.37 47.37 47.37 47.37
gopalakrishnan. v. 1.19 1.16 1.20 1.13 1.14
highcrestt global company... 2.66 2.66 2.66 2.66 2.66
swet realtors pvt. ltd. 1.33 1.33 1.33 1.33 1.33
umesh kumar gupta 1.42 1.81 1.81 1.86 1.86
varun jain 1.20 1.20 1.20 1.20 1.20
gautam chand jain 1.45 1.45 1.45 1.45 -

Annual Reports

Title Link
Title Link
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

 No Latest News available for this company.Report us

Godavari Drugs Stock Price Analysis and Quick Research Report. Is Godavari Drugs an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Godavari Drugs and its performance over the period of time. Godavari Drugs stock price today is Rs 84.5.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Godavari Drugs cash from the operating activity was Rs 18.4136 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Godavari Drugs has a Debt to Equity ratio of 1.4826 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Godavari Drugs , the EPS growth was 46.5717 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Godavari Drugs has OPM of 8.48965522082242 % which is a bad sign for profitability.
     
  • ROE: Godavari Drugs have a average ROE of 15.332 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Godavari Drugs is Rs 84.5. One can use valuation calculators of ticker to know if Godavari Drugs share price is undervalued or overvalued.
Last Updated on:
Brief about Godavari Drugs
X